[{"id":"e544b76d-26e2-4ad6-a6eb-87395873bc91","acronym":"","url":"https://clinicaltrials.gov/study/NCT07085338","created_at":"2025-08-02T14:49:08.314Z","updated_at":"2025-08-02T14:49:08.314Z","phase":"Phase 2","brief_title":"A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma","source_id_and_acronym":"NCT07085338","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan • Anktiva (nogapendekin alfa inbakicept-pmln) • Leukine (sargramostim) • humanised dinutuximab (Hu14.18K322A)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2025-07-25"},{"id":"5aa1495f-1183-4095-b05a-503274e48528","acronym":"","url":"https://clinicaltrials.gov/study/NCT04936529","created_at":"2021-06-23T17:52:37.826Z","updated_at":"2025-02-25T13:53:51.961Z","phase":"Phase 2","brief_title":"A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma","source_id_and_acronym":"NCT04936529","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYC • MYCN • CSF2","pipe":" | ","alterations":" MYCN amplification","tags":["MYC • MYCN • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"],"overall_status":"Recruiting","enrollment":" Enrollment 286","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 06/15/2025","study_completion_date":" 06/15/2025","last_update_posted":"2025-02-20"},{"id":"1c1948c5-7233-4ceb-9300-b6eaf01714a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00799110","created_at":"2021-01-18T03:02:02.415Z","updated_at":"2024-07-02T16:34:27.111Z","phase":"Phase 2","brief_title":"Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod","source_id_and_acronym":"NCT00799110","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zyclara (imiquimod)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 08/01/2008","start_date":" 08/01/2008","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-11"},{"id":"c1b27e69-5cb6-4c7f-a2c7-df42fb2ed239","acronym":"CYTOK-AZA","url":"https://clinicaltrials.gov/study/NCT06439199","created_at":"2024-06-08T04:34:20.475Z","updated_at":"2024-07-02T16:34:59.405Z","phase":"","brief_title":"Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy","source_id_and_acronym":"NCT06439199 - CYTOK-AZA","lead_sponsor":"Nantes University Hospital","biomarkers":" IL6 • TNFA • CXCL8 • IL10 • CSF2 • IL18 • IL17A • IL15 • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL10 • CSF2 • IL18 • IL17A • IL15 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/15/2024","start_date":" 06/15/2024","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 12/15/2026","study_completion_date":" 12/15/2026","last_update_posted":"2024-06-03"},{"id":"69c63340-f0e4-4849-b2f7-9e47c121183d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00458536","created_at":"2021-01-18T01:37:33.508Z","updated_at":"2024-07-02T16:35:11.645Z","phase":"Phase 1/2","brief_title":"Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF","source_id_and_acronym":"NCT00458536","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Dendritic cell renal cell carcinoma fusion vaccine"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 10/01/2004","start_date":" 10/01/2004","primary_txt":" Primary completion: 12/01/2014","primary_completion_date":" 12/01/2014","study_txt":" Completion: 07/01/2023","study_completion_date":" 07/01/2023","last_update_posted":"2024-04-03"},{"id":"894d41c8-fa82-4742-ae07-cc5efd0a178a","acronym":"EARDIS","url":"https://clinicaltrials.gov/study/NCT05648240","created_at":"2022-12-13T14:58:01.312Z","updated_at":"2024-07-02T16:35:20.013Z","phase":"","brief_title":"Proof-of-concept Study of Blood Markers of Tumor Dissemination in Patients With Versus Without Intestinal Polyps","source_id_and_acronym":"NCT05648240 - EARDIS","lead_sponsor":"Centre Hospitalier Universitaire de Nīmes","biomarkers":" CXCL12 • TIMP1 • CCL2 • CSF2 • CXCL1","pipe":"","alterations":" ","tags":["CXCL12 • TIMP1 • CCL2 • CSF2 • CXCL1"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 02/23/2023","start_date":" 02/23/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-02-09"},{"id":"f8076d31-2902-4362-b61e-6e70833ff082","acronym":"","url":"https://clinicaltrials.gov/study/NCT02774421","created_at":"2021-01-18T13:36:12.033Z","updated_at":"2024-07-02T16:35:25.210Z","phase":"Phase 1","brief_title":"Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma","source_id_and_acronym":"NCT02774421","lead_sponsor":"University of Colorado, Denver","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2023-12-25"},{"id":"f7ed64ab-75a3-4068-9e72-e78962cb42af","acronym":"","url":"https://clinicaltrials.gov/study/NCT00487305","created_at":"2021-01-18T01:44:29.000Z","updated_at":"2024-07-02T16:35:30.113Z","phase":"Phase 1","brief_title":"Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma","source_id_and_acronym":"NCT00487305","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e allogeneic K562-GM tumor cell vaccine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/01/2007","start_date":" 06/01/2007","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-11-07"},{"id":"16375f35-57e8-4891-ab8d-34d2a7ad1e54","acronym":"","url":"https://clinicaltrials.gov/study/NCT04495894","created_at":"2021-01-18T21:35:34.159Z","updated_at":"2024-07-02T16:35:32.024Z","phase":"Phase 1","brief_title":"Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma","source_id_and_acronym":"NCT04495894","lead_sponsor":"Emory University","biomarkers":" IL6 • TNFA • CXCL8 • IL2 • IL10 • CSF2 • IL1A • IL1B","pipe":" | ","alterations":" IL10 elevation","tags":["IL6 • TNFA • CXCL8 • IL2 • IL10 • CSF2 • IL1A • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL10 elevation"],"overall_status":"Recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-10-24"},{"id":"2d242dd0-61db-4f3f-9afc-4d328d0e9d66","acronym":"","url":"https://clinicaltrials.gov/study/NCT00458653","created_at":"2021-01-18T01:37:36.289Z","updated_at":"2024-07-02T16:35:45.212Z","phase":"Phase 1","brief_title":"Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma","source_id_and_acronym":"NCT00458653","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 04/01/2005","start_date":" 04/01/2005","primary_txt":" Primary completion: 04/01/2012","primary_completion_date":" 04/01/2012","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2023-06-22"},{"id":"214190d1-a059-4c23-b4d3-23fda520905e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01081223","created_at":"2021-01-18T04:15:50.013Z","updated_at":"2024-07-02T16:35:46.685Z","phase":"Phase 1/2","brief_title":"Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma","source_id_and_acronym":"NCT01081223","lead_sponsor":"TVAX Biomedical","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TVI-Brain-1"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 03/01/2011","primary_completion_date":" 03/01/2011","study_txt":" Completion: 03/01/2011","study_completion_date":" 03/01/2011","last_update_posted":"2023-06-01"},{"id":"05a7a7b4-9b3e-4998-8177-af641d62afb3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04386967","created_at":"2021-01-18T21:10:40.399Z","updated_at":"2024-07-02T16:35:48.866Z","phase":"Phase 1/2","brief_title":"OH2 Injection in Solid Tumors","source_id_and_acronym":"NCT04386967","lead_sponsor":"Binhui Biopharmaceutical Co., Ltd.","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • BS001"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/22/2018","start_date":" 11/22/2018","primary_txt":" Primary completion: 03/13/2024","primary_completion_date":" 03/13/2024","study_txt":" Completion: 12/13/2024","study_completion_date":" 12/13/2024","last_update_posted":"2023-05-05"},{"id":"47e375d8-f44c-473f-b1d3-1f3969d262b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02243397","created_at":"2021-01-18T10:31:41.963Z","updated_at":"2024-07-02T16:35:54.790Z","phase":"","brief_title":"Molecular and Cellular Analysis of Breast Cancer","source_id_and_acronym":"NCT02243397","lead_sponsor":"Stanford University","biomarkers":" CSF2","pipe":" | ","alterations":" CSF2 elevation","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CSF2 elevation"],"overall_status":"Suspended","enrollment":" Enrollment 500","initiation":"Initiation: 09/01/2014","start_date":" 09/01/2014","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-02-24"},{"id":"df82920f-9ea8-4681-a118-868fe5e96016","acronym":"","url":"https://clinicaltrials.gov/study/NCT01700673","created_at":"2021-01-18T07:23:36.364Z","updated_at":"2024-07-02T16:36:02.329Z","phase":"Phase 2","brief_title":"Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS","source_id_and_acronym":"NCT01700673","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 06/01/2013","start_date":" 06/01/2013","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 06/01/2020","study_completion_date":" 06/01/2020","last_update_posted":"2022-10-18"},{"id":"58e76544-2fc4-447d-b943-055695a4a703","acronym":"El-porCEA","url":"https://clinicaltrials.gov/study/NCT01064375","created_at":"2021-01-18T04:11:35.887Z","updated_at":"2024-07-02T16:36:05.120Z","phase":"Phase 1/2","brief_title":"Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer","source_id_and_acronym":"NCT01064375 - El-porCEA","lead_sponsor":"Maria Liljefors","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 12/01/2009","start_date":" 12/01/2009","primary_txt":" Primary completion: 03/01/2012","primary_completion_date":" 03/01/2012","study_txt":" Completion: 08/01/2016","study_completion_date":" 08/01/2016","last_update_posted":"2022-08-19"},{"id":"024e1277-d133-4914-a627-57cfe108a970","acronym":"TruCulture","url":"https://clinicaltrials.gov/study/NCT04127864","created_at":"2021-01-18T20:09:51.316Z","updated_at":"2024-07-02T16:36:05.964Z","phase":"","brief_title":"Perioperative Immune Function in Patients Undergoing Colorectal Cancer Surgery","source_id_and_acronym":"NCT04127864 - TruCulture","lead_sponsor":"University of Copenhagen","biomarkers":" IL6 • TNFA • CXCL8 • IL2 • IL10 • CCL2 • CSF2 • IL17A • IL13 • IL1B • IL4 • IL5 • IL7","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL2 • IL10 • CCL2 • CSF2 • IL17A • IL13 • IL1B • IL4 • IL5 • IL7"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/14/2019","start_date":" 10/14/2019","primary_txt":" Primary completion: 12/20/2019","primary_completion_date":" 12/20/2019","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2022-08-05"},{"id":"2abe584e-efd0-467e-a3cd-03637a2183a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01903330","created_at":"2021-01-18T08:34:13.635Z","updated_at":"2024-07-02T16:36:10.432Z","phase":"Phase 2","brief_title":"ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme","source_id_and_acronym":"NCT01903330","lead_sponsor":"Epitopoietic Research Corporation","biomarkers":" IL6 • IL2RA • CD4 • IL10 • CSF2","pipe":"","alterations":" ","tags":["IL6 • IL2RA • CD4 • IL10 • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cyclophosphamide • Mvasi (bevacizumab-awwb) • Zirabev (bevacizumab-bvzr) • Sitoiganap (ERC1671) • Leukine (sargramostim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 03/01/2014","start_date":" 03/01/2014","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2022-05-16"},{"id":"b1a09e70-c244-4244-8a46-3763e9f48327","acronym":"","url":"https://clinicaltrials.gov/study/NCT00072358","created_at":"2021-01-18T00:11:14.276Z","updated_at":"2024-07-02T16:36:10.441Z","phase":"Phase 2","brief_title":"Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma","source_id_and_acronym":"NCT00072358","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYCN • CSF2","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 291","initiation":"Initiation: 07/01/2003","start_date":" 07/01/2003","primary_txt":" Primary completion: 01/15/2021","primary_completion_date":" 01/15/2021","study_txt":" Completion: 01/15/2021","study_completion_date":" 01/15/2021","last_update_posted":"2022-05-16"},{"id":"71d64c54-130c-43f1-812c-328c659a34d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00317603","created_at":"2021-01-18T01:05:39.497Z","updated_at":"2024-07-02T16:36:14.248Z","phase":"Phase 1","brief_title":"Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients","source_id_and_acronym":"NCT00317603","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • CSF2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 01/01/2006","start_date":" 01/01/2006","primary_txt":" Primary completion: 05/01/2008","primary_completion_date":" 05/01/2008","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2022-04-01"},{"id":"95ffb9c5-9f63-4d77-b99e-90934b8def8c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00880464","created_at":"2021-01-18T03:22:06.796Z","updated_at":"2024-07-02T16:36:14.275Z","phase":"Phase 1","brief_title":"Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer","source_id_and_acronym":"NCT00880464","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • CSF2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 01/01/2006","start_date":" 01/01/2006","primary_txt":" Primary completion: 10/01/2011","primary_completion_date":" 10/01/2011","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2022-04-01"},{"id":"71ce3557-7186-4552-8aeb-83c3fb94cbdc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01061840","created_at":"2021-01-18T04:10:59.745Z","updated_at":"2024-07-02T16:36:15.390Z","phase":"Phase 1","brief_title":"Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer","source_id_and_acronym":"NCT01061840","lead_sponsor":"Gradalis, Inc.","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vigil (gemogenovatucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2009","start_date":" 12/01/2009","primary_txt":" Primary completion: 12/06/2018","primary_completion_date":" 12/06/2018","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2022-03-15"},{"id":"58983750-f972-41eb-a87b-5b3ad10f44fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT03243786","created_at":"2021-01-18T16:01:33.705Z","updated_at":"2024-07-02T16:36:20.089Z","phase":"","brief_title":"Stay on Track: A Study of Exercise Effects During Radiation","source_id_and_acronym":"NCT03243786","lead_sponsor":"Medical College of Wisconsin","biomarkers":" IFNG • IL6 • TNFA • CXCL8 • IL10 • CSF2 • IL1A • IL1B • IL4 • LEP","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • CXCL8 • IL10 • CSF2 • IL1A • IL1B • IL4 • LEP"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 04/12/2017","start_date":" 04/12/2017","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":" Completion: 10/31/2018","study_completion_date":" 10/31/2018","last_update_posted":"2021-11-30"},{"id":"a6514c66-2b5c-47bf-917a-f32673da1dde","acronym":"","url":"https://clinicaltrials.gov/study/NCT00599170","created_at":"2021-01-18T02:13:09.548Z","updated_at":"2024-07-02T16:36:20.601Z","phase":"Phase 2","brief_title":"Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT00599170","lead_sponsor":"University of Southern California","biomarkers":" CD20 • CSF2","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 01/10/2008","start_date":" 01/10/2008","primary_txt":" Primary completion: 01/10/2020","primary_completion_date":" 01/10/2020","study_txt":" Completion: 01/10/2021","study_completion_date":" 01/10/2021","last_update_posted":"2021-11-17"},{"id":"91461f09-f8c2-4475-8c9a-281bf9820b72","acronym":"","url":"https://clinicaltrials.gov/study/NCT00293462","created_at":"2021-07-30T23:52:26.673Z","updated_at":"2024-07-02T16:36:27.215Z","phase":"Phase 3","brief_title":"GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer","source_id_and_acronym":"NCT00293462","lead_sponsor":"Marilyn Dodd","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 91","initiation":"Initiation: 06/07/2005","start_date":" 06/07/2005","primary_txt":" Primary completion: 12/31/2009","primary_completion_date":" 12/31/2009","study_txt":" Completion: 12/31/2009","study_completion_date":" 12/31/2009","last_update_posted":"2021-07-30"}]